This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk01: Good afternoon, and thank you for joining us today to discuss the results for LifeMD's second quarter of 2021, ended June 30th, 2021. Joining the call today are Justin Treiber, Chairman and Chief Executive Officer, and Mark Benison, Chief Financial Officer of LifeMD. Following management's prepared remarks, we will open the call for question and answer session. I would like to remind everyone that today's call is being hosted via webcast, and the recording will be made available via the link in today's press release. which is available in the investor relations section of the company's website. Before we begin, I would like to remind everyone that during this call, the company will make a number of forward-looking statements which are subject to numerous risks and uncertainties that may cause the company's actual results to differ materially from those projected. These risks and uncertainties are described in the company's 10-K and 10-Q filings and within other filings that LifeMD may make with the SEC from time to time. Forward-looking statements made during this call are based on current information available to the company as of today. The company assumes no obligation to update or revise any forward-looking statements after today's call, except as required by law. Also, please note that management will be discussing certain non-GAAP financial measures that the company believes is important to evaluating LifeMD's performance. Details on the relationship between these non-GAAP measures to the most comparable GAAP measures and reconciliations thereof can be found in the press release issued earlier today. Finally, I would like to remind everyone that today's call is being recorded and will be available for replay in the investor relations section of the company's website. Now, I'd like to turn the call over to Life Indies CEO, Justin Shriver. Please go ahead.
spk03: Thank you, operator, and good afternoon, everyone. Thank you for joining us today to discuss our second quarter 2021 results. Our strong top-line performance continued this quarter, building on top of the incredible momentum we saw from the start of this fiscal year. Even with pandemic restrictions being largely lifted, we continue to see record demand for our telehealth products and services. Telehealth orders were up 155% over the same quarter last year, Our subscription-based patient customer numbers also continued to grow, with a record 93% of revenue being generated by recurring subscriptions. Patient retention across all brands remained at record levels. All of this added up to LifeMD producing record revenues of $22.3 million, up 145% from the year-ago period. Perhaps most impressive was that despite a significant 20% increase in media rates across our core digital channels, our acquisition team was able to drive an 8% sequential decrease in customer acquisition costs. This optimization allowed us to double down on our discretionary marketing investment to drive an 11% sequential increase in new patient acquisitions per day in comparable brands and further increase our market share. During the quarter, we also began marketing our newest teledermatology brand, NavaMD. Early results have been promising with strong reception from patients. NavaMD customer acquisition costs have so far been extremely favorable with an estimated payback on investment of two to four months. As we've said previously, we believe that NavaMD will be a very meaningful top line and profitable contributor over the long term. Organizationally, we made several important key strategic hires, especially with our new president, Alex Muranoff. Alex brings to us over 20 years of experience in business development, mergers and acquisitions, and corporate strategy, as well as extensive experience in the pharmaceutical industry. This includes leading transactions in the pharma space, totaling over $5 billion. His expertise will allow us to broaden and deepen our telehealth brands and product offerings, in areas where we believe we can continue to disrupt and demonstrate our industry leadership in the direct-to-consumer healthcare market. We continue to place a strong emphasis on our digital health technology platform, which is enabling a robust patient care process that provides unlimited expandability across a multitude of indications and healthcare services. To highlight this expandability, we recently announced three exciting partnerships that will enable us to augment our upcoming launch of the LifeMD primary care platform. These transformational partnerships include a world-class provider of laboratory services and Axel Health, a leading provider of at-home diagnostic services. In combination, these new partners will provide patients of our telehealth platform access to over 150 commonly ordered laboratory tests, a wide range of in-home diagnostic services, and access to over 2,000 national laboratory locations, all at preferred pricing. Next, we also announced a partnership with Particle Health, a leading provider of HIPAA compliant electronic medical records data that will transform the way that our affiliated medical providers and their patients access and utilize real-time medical data to personalize their care. All of these partnerships have positioned us very well for the launch of our primary care platform, LifeMD, this fall, which we expect to rapidly disrupt the primary care market. In summary, we had a great second quarter marked by the successful launch of the NavaMD brand, tremendous performance of our acquisition marketing platform, elevation of our technology infrastructure, and the consummation of several differentiating partnerships. Looking ahead, we're more confident than ever in our ability to be a market leader in the direct-to-patient telehealth industry. With that, I will now turn the call over to our CFO, Mark Benethen, who will provide a summary of this quarter's financial results. Mark?
spk02: Thank you, Justin, and good afternoon, everyone. As Justin mentioned, during the quarter, we continued to execute with strong top-line and operational performance. We grew our offerings, expanded our existing brands, launched new business lines and capabilities, and improved our efficiencies, all while maintaining a high level of service. A key factor driving our strong performance this quarter was how we were able to drive improving unit economics by further optimizing our media strategy to drive an 8% sequential decrease in our CAC. This was a remarkable achievement given how at the same time digital media rates across our channels increased by more than 20%. Adjusting for this sizable rate increase, our team was actually able to drive an approximate 30% improvement in our media efficiency on a sequential basis, while also acquiring new patient customers at a per day rate that was 11% higher than the previous quarter. Leveraging this performance in our strong unit economics, which pay back in two to four months, we made the conscious decision to efficiently increase our total discretionary acquisition marketing spend during the quarter to capture market share. Taking a closer look at our results, revenue in the second quarter of 2021 totaled the record $22.3 million, up 145% as compared to the same quarter a year ago. and up 23% sequentially. And this was largely recurring revenue with 93% of our revenue generated by recurring subscriptions in the second quarter of 2021, which was just 56% in the same year-ago period. And our retention on these new subscribers remains very strong. In fact, 60% of our revenue this quarter came from billings of already existing subscribers as compared to just 22% of our revenue in the same year-ago quarter. Telehealth net revenues grew over 100% to $15.8 million. Our Legal Simply subsidiary contributed net revenue of $6.5 million, up 434% from the year-ago quarter. Telehealth order volume grew 155% versus the year-ago period to 199,674 orders. Following this continued excellent performance, we are reiterating our previously raised full-year 2021 revenue guidance of $90 to $100 million, reflecting annual growth in 2021 of between 141% and 168% versus 2020. Gross profit in the second quarter increased 145% to 18.1 million, compared to 7.4 million in the same year-ago quarter. Gross profit as a percentage of revenue in the second quarter of 2021 was 81.2% compared to 81.4% in the same year-ago quarter. Starting this quarter, we commenced reporting platform contribution, a non-GAAP financial measure defined as GAAP operating loss before general and administrative expenses, excluding payment processing fees, selling and marketing expenses, and other operating expenses. We consider platform contribution to be an important non-GAAP financial measure which monitors our performance based on the direct costs of delivering the products and services we sell across our brands. We believe platform contribution is useful to measure how we are controlling our direct variable costs, and how effectively we retain our providers, patients, and customer subscribers. Additionally, platform contribution is a good leading indicator of profitability for our company. Platform contribution in the second quarter totaled $16.5 million compared to $6.7 million in the same year-ago quarter, an increase of 145%. Now turning to operating expenses. Operating expense in the second quarter of 2021 was $34.2 million, up from $10.6 million in the same year-ago quarter. The increase was primarily due to increases of discretionary growth, selling and marketing expenses of $14 million, general and administrative expenses of $8.6 million, other operating expenses of $715,000, and customer service expenses of $384,000. development costs decreased by $47,000. G&A expenses for the second quarter of 2021 also included non-cash expenses for stock-based comp and amortization expenses of $3.3 million. The increase in operating expenses compared to the year-ago period was associated with investments made to scale our infrastructure to support a rapidly growing diversified telehealth business offering treatment for a range of chronic conditions and primary care. We expect to leverage these investments starting in 2022 and gradually reduce quarterly EBITDA losses in 2022 as we scale the business to EBITDA breakeven by the end of 2022. Our GAAP net loss attributable to common stockholders for the second quarter totaled $16.8 million, or 64 cents per share. This compares to a net loss attributable to common stockholders of 3.4 million or 27 cents per share in the second quarter of 2020. Adjusted EPS is a non-GAAP measure that excludes 2.5 million in non-cash stock-based compensation expense and 946,000 of non-recurring financing transaction expenses. This figure totals a loss of 51 cents per share for the second quarter as compared to a loss of $0.24 in the same year-ago period. Adjusted EBITDA, a non-GAAP financial measure which factors out non-cash stock-based compensation, depreciation and amortization expenses, financing transaction expenses, litigation costs and interest expenses, totaled the loss of $12 million in the second quarter of 2021. This compares to an adjusted EBITDA loss of $2.1 million in the same year-ago quarter. Now turning to our balance sheet. Cash totaled 17.4 million as of June 30th, 2021, as compared to 9.2 million as of December 31st, 2020. As we continue to scale and invest in the rapid expansion of our business with strong unit economics, we remain focused on building our balance sheet with the interests of shareholders in mind. To this end, we expect to complete an additional non or minimally dilutive capital raise this year to further strengthen our balance sheet. This wraps up our financial results. I'd now like to turn the call back over to Justin. Justin?
spk03: Thanks, Mark. Overall, it was a tremendous second quarter. We elevated our infrastructure with the appointment of an exceptional president, consummated three transformational partnerships immediately after the quarter end, drove outstanding acquisition marketing performance despite significant cost headwinds in the media market, launched NavaMD, and laid the foundation for what we expect to be a very successful upcoming launch of our primary care platform, LifeMD. The strong performance in the second quarter has carried into the current quarter. We're continuing to see very strong demand for our products and services. Just recently, we set our new single-day record for new patient acquisitions. In closing, our numbers speak for themselves, and with each passing day, our vision of disrupting healthcare by building the leading telehealth business is coming to fruition. Our continued growth will depend on the strength of our team, technology, and operations. To support our immense vision and efforts, we have strengthened our foundation significantly in the last quarter, setting up the continued growth of our existing businesses and the launch of new brands and offerings, such as our primary care platform, while remaining on track to reach profitability by the end of 2022, barring any significant investments in new brands or verticals. We still have a lot of things to accomplish in healthcare, and we remain focused on continuing to build our position as a leader in direct-to-patient telehealth. We'll do this by delivering unparalleled care through our affiliated providers as we continue to disrupt traditional healthcare. So thanks again to our providers and their patients our team, and our shareholders. It wouldn't be possible to do what we do without everyone's support. With that, I would like to open the call for Q&A.
spk01: Thank you. And everyone, to ask a question, please press star then one on your telephone keypad. Please note that if you're on a speakerphone, we ask you to please pick up your handset or depress your mute function before asking your question. And that is star one to ask a question. And we'll go first to Andrew DeSilva of B. Reilly Securities.
spk06: Good afternoon. Thanks for taking my questions and really congrats on all the progress. A few quick ones for me. First, just given the vaccination progress and then loosened restrictions during the second quarter, can you talk around retention and what you saw from a stickiness standpoint? And is it fair to assume those trends are holding true into the summer?
spk02: Yeah, thanks, Andy. I can tell you that in the second quarter, our retention was comparable to what it was in the first quarter, continued to remain very high across our prescription products. Within the first billing cycle, we continue to see 75% to 80% retention within those first three to four months after the person becomes and initial patient, and then continued strong unit economics with the payback within the first call of two to four months, and then 2X return in the first year. So the pandemic restrictions loosening have really had no impact on our business. In fact, we are actually seeing improvements in retention thus far as we've started the third quarter. So business, both from a new acquisition standpoint and a retention standpoint, has actually been performing at record levels post a lot of the restrictions being lifted.
spk06: That's really interesting. Okay, moving over to some strategic initiatives, you're obviously highly focused on that. You brought on Alex, who's clearly driving a lot of what's going on. I'm curious how that pipeline looks and what kinds of opportunities we should be thinking about going forward or where the business can be bolstered better. And with the recent diagnostic partnership, I was curious if that positions you to introduce things like testosterone replacement therapy.
spk04: Yeah, Andy, this is Justin.
spk03: With regards to the biz dev pipeline, you know, Alex has done an exceptional, you know, job in the first 90 days. Definitely, you know, I think that what we expected was right on. I think he's exceeded our expectations. I would, I would estimate that we have at least 10, you know, potential pharma partnerships with, with pharmaceutical companies that are in the pipeline, some more promising than others, but a lot of very exciting stuff there, especially considering, you know, Alex is only 90 days in. And then your second question, I'm sorry, I kind of broke up.
spk06: Yeah, as far as diagnostic partnerships go, or the diagnostic partnership goes, does that position you to be able to provide testosterone replacement therapy across your platform?
spk03: It could be used for an offering like testosterone replacement therapy. You know, we've stayed away from controlled substances, and, you know, so going into the the testosterone space, you know, and testosterone replacement therapies is not something that's kind of on the near-term radar screen. But, you know, certainly, look, the relationship with Quest and Axel Health, you know, first and foremost for our virtual primary care offering, it's essential. You know, we have very preferential pricing, you know, cash pay pricing on you know, 150 very common, you know, tests where our patients can walk into, you know, any of any Quest location across the country. And, you know, no one will avoid a diagnostic, you know, a lab test because of the cost. I can assure you that. So that was, that's really exciting for us. And then, you know, secondly, you know, Axel Health gives us the ability to go, you know, and send a phlebotomist to the patient's home. to collect blood work if that's more convenient for them and they don't mind paying an additional fee for that. So many of these condition-specific, indication-specific telehealth offerings will require lab work. Testosterone therapy is one example. So we look at this as a really important piece of the puzzle as we continue to diversify our portfolio of offerings.
spk06: Great, Collin. Thank you. Last thing for me, should we expect tax or CPAs to continue to improve? And how should we manage that thought process with overall sales and marketing spend? And can you also give a little context around the ad rate environment currently? And maybe how we should think about that for the rest of the year, any seasonality trends would be useful.
spk02: Yeah, this is Mark. So with CACs, we've obviously now made two quarters of sequential improvements. The first quarter, we improved 15% to 20% by brand versus the prior quarter. And then this quarter, we improved another 8% sequentially against the first quarter. And actually, our improvements would have been close to 25% to 30% had the media market not seen rates that increased by more than 20%. so we're able to obviously more than offset that. I think going forward, there may be some, there will definitely longer term heading into next year be some improvements in CACs. In the shorter term, as we head into Q3 and Q4, I certainly would expect CAC levels to be pretty comparable to where we've driven them today. We've actually driven them to pretty very cost effective and very cost efficient levels. In fact, most companies in the second quarter experienced massive increases in their marketing and had to dial back on the amount of growth investment. On the other hand, what our approach has been, we've been able to significantly optimize our media. And we believe that, you know, that's obviously one of our strong suits, direct to consumer acquisition. And we redeployed capital and reinvested back into sales and marketing expense in order to go out and grab market share, which is, only going to lead to more significant revenue growth in the future and ultimately profitability growth. How we should think about sales and marketing expense going forward is I would expect over the next couple of quarters to see sales and marketing as a percent of revenue to be fairly comparable to where we are today, possibly a little bit better in the next one to two quarters. But the reality is we have the ability to acquire new customers, patients at very efficient levels that pay back in a very quick period of time. We're going to invest and go after that. The market size that we're going after is approaching a trillion dollars. So there's a tremendous amount of opportunity for us to leverage those strengths and capabilities. Whereas, you know, we've definitely seen companies that, you know, have to go the other direction and certainly pull back on their advertising spend, which long term does catch up with you. as far as acquiring new patients and then retaining those customers.
spk05: Thanks, Mark. Thanks, Justin, for taking my questions. Good luck going forward and congrats on the progress. Thank you. Thanks, Andy. Thanks, Andy.
spk01: And our next question will come from Mikael Kaiserman of BTIG.
spk00: Good afternoon, guys. This is Mikael in for David Larson. Um, thanks for, uh, all the clarifications and progress. Um, just a couple of questions, uh, on my side, um, maybe we can, uh, start with Nava and, and sort of the launch. I know you mentioned that, uh, the two to four month payback period. Um, but maybe you can just better frame, you know, how the membership volumes have been looking there, you know, how you're thinking about the overall market potential there and, and sort of, uh, a sense of your margin profile for that business.
spk04: Yeah, so this is Mark.
spk02: So NAVA, you know, in general, we launched aggressive marketing in the second quarter. We obviously launched the business in the first quarter, but it took a little bit of time to get some certification, so we started going to market around halfway through the second quarter. We saw strong patient reception, but what we've done is the initial traffic that we were running through that particular brand, at least for the first couple of months. We've relaxed that at this point. Capped the amount of traffic. So if we were seeking to acquire a certain amount of patients, we capped it at a percentage of that per day. And every single day that we went to market going through that, we could have easily exceeded those caps. But we wanted to obviously get a read on the rebills, which started to trickle in in the month of July. What I can say is we've obviously seen strong initial rebuild numbers coming out of the brand, very strong patient acquisition numbers, double-digit tax that were the lowest that we've seen across any brand in the portfolio, and tax that enable us, obviously, to pay back in that two- to four-month timeframe. As far as going forward, this market has tremendous potential. potential. It can be even larger than the Rex market, which is already a multi hundred billion dollar TAM. So, you know, we think looking ahead over the next 12 to 24 months that there's no reason that this business can't be along the lines of the size of what a Rex business can be possibly bigger, possibly a little bit smaller, but it's a little hard to say exactly what it will be other than we know that we have a brand that can be really big.
spk00: Got it. Thank you for that. And maybe just on your primary care solution launch this fall, if you can just maybe, you know, frame some of your membership growth, you know, potential there and how you're going to be really leveraging your partnerships with Axis Health and Particle Health as well to really grow that business and that differentiation. So it would be helpful to get more context there.
spk03: Yeah, this is Justin. I'll comment on that. You know, I mean, anytime we launch something, we're going to be conservative out of the gate. The technology platform that we've built for LifeMD and our subscription-based primary care offering is incredible. It's the best technology that we've ever built. We're launching iOS and Android mobile apps as well, and So we're intentionally going to, you know, onboard patients, you know, in a conservative manner. So I don't, you know, I don't know whether that's 25, 50 patients a day initially for the first month or two, but, you know, it's a little premature, I think, to give estimates on the growth. But I think what I'm okay saying is, you know, look, we're going to be, you know, conservative, you know, throughout the fall with putting patients on the platform and We have a lot of new providers that we've affiliated providers that, you know, we've brought on board for our LifeMD offering. You know, a lot of these new technology partnerships, new technology of our own. So we're going to be conservative with it, but we're really excited to demonstrate this, you know, to the markets, you know, this year that, hey, this is scaling and we've onboarded you know, sufficient number of patients to, you know, to really prove this out. And, you know, hopefully we can show by the end of the year that this is going to be a very big business and a meaningful part of the LifeMD story moving forward.
spk04: Got it.
spk00: And maybe just one last one to kind of elaborate on the improvement in CAC that you guys have been seeing over the last couple of quarters. You know, just your thoughts on that flowing into kind of the EBITDA margins and sort of starting to see, you know, greater improvement on that front. And, you know, maybe when you sort of expect that you might hit break even as well on that front.
spk02: Yeah, smart. So, you know, as I've indicated on the call, we expect to be hitting EBITDA break even by the end of 2022 and starting to see some leverage improvements in 2022. As far as the CAC improvements flowing into EBITDA margin over the next one to two quarters, we do not expect to see improvements in EBITDA margin over the next quarter with some slight improvements in the fourth quarter of this year. And the reason for that is while we're able to improve CACs and significantly increase our efficiency, as I think we showed in the second quarter, we're able to do that and also acquire more new customers that we're able to retain very well and earn terrific unit economics on. So in the short term, we're going to reinvest and redeploy capital towards continuing to aggressively grow our market share, which we think will return over the long term and really starting to pan out next year, much more significant growth than if we started taking all of that to the bottom line and going through to improve even the margin in the short term at the expense of the next call at 12, 24, 36 months.
spk04: Thank you guys very much. I appreciate all the updates and congrats on all the progress. Thank you.
spk01: And with that, everyone. And with that, everyone, that does conclude today's question and answer session. I would like to turn things back to Justin Schreiber, CEO, for final comments.
spk04: No final comments.
spk03: Just thank you to everyone for participating in this call. I appreciate everybody's support and look forward to giving you an even more positive update next quarter.
spk01: And with that everyone, that does conclude today's call. We'd like to thank you again for your participation. You may now disconnect.
Disclaimer